HKSE - Delayed Quote HKD

Venus Medtech (Hangzhou) Inc. (2500.HK)

2.320

-0.060

(-2.52%)

As of 11:43:47 AM GMT+8. Market Open.

Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations

Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year ended December 31, 2024 ("the Year"), demonstrating significant improvements in profitability and operational discipline despite market challenges.

PR Newswire last month

VMTHF
Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech (Hangzhou) Inc. (Venus Medtech, 02500.HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced that its in-house developed next-generation balloon-expandable dry-tissue transcatheter aortic valve replacement (TAVR) system, Venus-Vitae, successfully completed two inaugural implantations as part of its global multicenter pivotal trial, Venus-Vitae SMART-ALIGN, at Prince of Wales Hospital in Hong Kong, China.

PR Newswire 8 months ago

VMTHF
Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

Venus Medtech (02500. HK), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced today that its in-house developed innovative transcatheter pulmonic valve replacement (TPVR) system, VenusP-Valve, has completed its first implantation in the PROTEUS IDE Pivotal Clinical Study at the University of Virginia School of Medicine. This momentous procedure was performed by a multidisciplinary team coordinated by Prof. Scott Lim and Prof. Mich

CNW Group 11 months ago

VMTHF

Performance Overview

Return	2500.HK	HANG SENG INDEX (^HSI)
YTD	-58.72%	+18.76%
1-Year	-58.72%	+28.94%
3-Year	-83.16%	+10.02%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Venus Medtech (Hangzhou) Inc. (2500.HK)

Venus Medtech Reports 2024 Annual Results: Profitability Surges with Robust Global Expansion and Innovations

Venus Medtech Venus-Vitae Completes First Two Implantations in SMART-ALIGN Pivotal Clinical Study

Venus Medtech VenusP-Valve Completed First Implantation in IDE Pivotal Clinical Study in U.S.

Performance Overview